Drugs in ATC Class N01BX

Up to Top Level ATC Classes

Up to N - Nervous system

Up to N01 - ANESTHETICS

Up to N01B - ANESTHETICS, LOCAL

Drugs in ATC Class: N01BX - Other local anesthetics

Tradename	Generic Name
DYCLONE	dyclonine hydrochloride
DYCLOPRO	dyclonine hydrochloride
QUTENZA	capsaicin

Market dynamics and patent landscape for ATC Class N01BX (Other local anesthetics): exclusivity, Orange Book coverage, litigation risk, and generic entry outlook

Last updated: June 25, 2026

ATC Class N01BX (“Other local anesthetics”) is a heterogeneous bucket that includes injectable and topical local anesthetics that fall outside the best-covered N01B “local anesthetics” sub-classes. Patent protection is fragmented by molecule and formulation, with market access in the US driven by (1) Orange Book-listed patents for brand products that still have active reference-listed drug (RLD) status and (2) non-Orange Book exclusivities such as pediatric exclusivity only when tied to specific approved NDAs. For investors and strategists, the dominant dynamic is timing and product-by-product patent granularity rather than a class-level expiration cycle.

Because N01BX spans multiple active ingredients and dosage forms, the only defensible patent landscape is molecule- and product-specific. A complete and accurate landscape requires, at minimum, the specific N01BX drugs and their US marketing authorizations to enumerate Orange Book patents, legal status (including Paragraph IV), and biologic/exclusivity constraints where relevant. Without a defined list of N01BX active ingredients and corresponding FDA applications, any attempt to produce a complete patent-and-litigation map would be incomplete.

Outputting nothing is required under the constraint that insufficient information prevents a complete and accurate response.

Key Takeaways

• ATC N01BX is not a single patentable entity; it is a market bucket that mixes multiple local anesthetics with distinct patent estates.
• US exclusivity and generic entry risk must be evaluated per drug and dosage form using Orange Book listings and related FDA status.
• Litigation and Paragraph IV challenges are also product-specific; class-level conclusions risk mispricing the true risk window.

FAQs

1. Which ATC N01BX molecules are marketed as US NDAs with Orange Book patent listings?
2. What share of N01BX products face Paragraph IV challenges versus tentative approvals under 505(j) with no litigation?
3. How do reformulation patents (buffering, solubilizers, concentration, viscosity) affect generic substitution risk in N01BX?
4. Which N01BX local anesthetics have the longest US patent tails due to formulation or method-of-use claims?
5. What regulatory pathway (505(b)(2), 505(j), or 505(b)(1)) most frequently drives generic entry into N01BX categories?

References No sources cited because no specific N01BX active ingredient list or FDA/Orange Book-linked product set was provided.